EP0229718A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Labelling blood cells
Assignee: GE Healthcare Ltd
•
Filing: 1987-01-14
•
Granted: —
•
Expires: 2007-01-14
Abstract
Abstract European Patent Specification 194843A describes a family of technetium-99m complexes of propylene amine oximes, of which that having structure 2 is typical, which have interesting brain retention properties. This invention provides a method of labelling blood cells by incubating a suspension of the cells with such a technetium-99m complex of a propylene amine oxime. For granular sites, the method has been tested clinically and found superior to 111-oxine.
Inventors
- 👤 James Duncan Kelly
- 👤 Rudi Dominique Neirinckx
- 👤 David Peter Nowotnik
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 20:28
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/1203; A61K2123/00
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
43 words
A method of labelling blood cells by incubating a suspension of the blood cells with a neutral lipophilic technetium-99m complex of a propylene amine oxime having the general structure 1, where one or each of the starred carbon atoms carries one hydrogen atom.
Claim 2
Independent Claim
43 words
A method of labelling blood cells by incubating a suspension of the blood cells with a neutral lipophilic technetium-99m complex of a propylene amine oxime having the general structure 1, where one or each of the starred carbon atoms carries one hydrogen atom.
Claim 3
Dependent Claim
18 words
A method as claimed in claim 1, wherein the suspension of blood cells is substantially free of plasma.
Claim 4
Dependent Claim
16 words
A method as claimed in claim 1 or claim 2, wherein the blood cells are leucocytes.
Claim 5
Dependent Claim
20 words
A method as claimed in claim 3, wherein the cell concentration of the leucocyte suspension is at least 10⁶ cells/ml.
Claim 6
Dependent Claim
16 words
A method as claimed in claim 1 or claim 2, wherein the blood cells are erythrocytes.
Claim 7
Independent Claim
85 words
A method as claimed in any one of claims 1 to 5, wherein the propylene amine oxime has the formula 3:- where each R is H, alkyl, aryl, aralkyl, cycloalkyl, CF₃, CONX₂ or C₆H₄OCH₃. R¹ is H, alkyl aryl, aralkyl, cycloalkyl or CF₃, each R² is alkyl, aryl, aralkyl, cycloalkyl or CF₃, or R and R² together form part of a cycloalkyl ring, each of R³, R⁴ and R⁵ is H, alkyl, aryl, aralkyl cycloalkyl or CF₃, and X is H, CH₃, C₂H₅ or C₆H₅.
Claim 8
Independent Claim
21 words
A method as claimed in any one of claims 1 to 6, wherein the propylene amine oxime is 4,8-diaza-3,6,6,9-tetramethylundecane-2,10-dione bis oxime.
Claim 9
Dependent Claim
18 words
A method as claimed in claim 7, wherein the d,l- form of the propylene amine oxime is used.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.